Free tool
FAERS Monitor: Tecentriq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761034 or its brand name (Tecentriq, Atezolizumab). Reports on generic versions are filed under their own applications.
Reports
39,719
Serious
37,952
96% of reports
Hospitalization
16,712
Death reported
10,079
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death4,361
- off label use3,721
- disease progression2,260
- pyrexia1,803
- diarrhoea1,750
- fatigue1,560
- anaemia1,387
- pneumonia1,160
- decreased appetite1,143
- hypothyroidism1,132
- nausea1,095
- dyspnoea1,061
- hypertension1,028
- pneumonitis995
- rash994
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 3 |
| 2015 | 25 |
| 2016 | 603 |
| 2017 | 1,159 |
| 2018 | 1,889 |
| 2019 | 2,604 |
| 2020 | 3,354 |
| 2021 | 5,267 |
| 2022 | 5,804 |
| 2023 | 5,878 |
| 2024 | 5,155 |
| 2025 | 4,659 |
| 2026 | 3,317 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,014,440 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pneumonitisSignal | 995 | 20.0 | 18.8 | 17,351 |
| hypothyroidismSignal | 1,132 | 19.4 | 18.3 | 19,095 |
| disease progressionSignal | 2,260 | 10.3 | 9.9 | 18,693 |
| anaemiaSignal | 1,387 | 3.9 | 3.7 | 2,957 |
| pyrexiaSignal | 1,803 | 2.8 | 2.6 | 2,058 |
| deathSignal | 4,361 | 2.7 | 2.6 | 4,798 |
| decreased appetiteSignal | 1,143 | 2.6 | 2.5 | 1,144 |
| hypertensionSignal | 1,028 | 2.6 | 2.4 | 997 |
| off label useSignal | 3,721 | 2.3 | 2.2 | 2,701 |
| pneumonia | 1,160 | 1.9 | 1.8 | 500 |
| diarrhoea | 1,750 | 1.4 | 1.4 | 239 |
| rash | 994 | 1.2 | 1.1 | 36 |
| fatigue | 1,560 | 1.1 | 1.0 | 6 |
| dyspnoea | 1,061 | 1.0 | 0.9 | 0 |
| nausea | 1,095 | 0.7 | 0.7 | 111 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.